Lymphatic Anomaly Gene Panel Diagnosis and Targeted Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for lymphatic anomalies lack genetic biomarkers and effective therapeutics targeting the underlying genetic markers associated with disorders such as lymphangiomatosis and generalized lymphatic anomaly, leading to inconsistent classification and inadequate treatment options.
Innovation Solution
A diagnostic method involving genetic testing for single nucleotide variants (SNVs) in specific genes like PTPN11, KRAS, BRAF, SOS1, ITGA9, RASA1, RAF1, RIT1, PEIZO1, EPHB4, NF1, and CBL, followed by targeted treatment with MEK/ERK inhibitors, mTOR inhibitors, or combinations thereof, to treat lymphatic anomalies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If genetic testing for SNVs in multiple genes is performed, then diagnostic accuracy is improved, but device complexity and cost increase
Solution Approach 1:
The diagnostic approach is segmented into two distinct pathways: (1) testing for pathogenic SNVs in a defined panel of 12 genes (PTPN11, KRAS, BRAF, SOS1, ITGA9, RASA1, RAF1, RIT1, PEIZO1, EPHB4, NF1, CBL), and (2) testing for CNVs in the same genes. This segmentation allows the complex genetic analysis to be organized into manageable, targeted assays rather than whole-genome sequencing, improving diagnostic accuracy while controlling complexity.
Solution Approach 2:
The same gene panel serves multiple diagnostic functions: detecting both SNVs and CNVs, identifying patients who will respond to MEK/ERK inhibitors, mTOR inhibitors, or combination therapies, and providing a unified diagnostic framework for diverse lymphatic anomalies including LAM, GLA, and CCLA. This multi-functionality reduces the need for multiple separate tests.
2Reliability
If targeted therapy with MEK/ERK inhibitors and mTOR inhibitors is administered, then treatment effectiveness is improved, but device complexity increases
Solution Approach 1:
The treatment approach applies local quality by matching specific therapeutic regimens to specific genetic mutations identified in the diagnostic phase. For example, patients with PTPN11 mutations receive MEK/ERK inhibitors, while those with PIK3CA mutations receive mTOR inhibitors, and certain combinations receive both. This personalized matching improves treatment effectiveness while managing complexity through evidence-based guidelines.
Solution Approach 2:
The treatment strategy incorporates feedback from the genetic test results to determine the appropriate therapy. The diagnostic information about specific SNVs and CNVs provides feedback that guides selection of MEK/ERK inhibitors, mTOR inhibitors, or combination therapy, ensuring that treatment is tailored to the patient's specific molecular profile rather than using a one-size-fits-all approach.
Data Source
AI summary
Compositions and methods for the diagnosis and treatment of lymphatic anomaly are disclosed.